Aurobindo Pharma's subsidiary CuraTeQ expands licensing deal with Orion for biosimilars distribution in select European markets

11 Jan 2022 , 01:54 PM

Aurobindo Pharma on Tuesday announced that its subsidiary CuraTeQ Biologics Pvt Ltd. (CuraTeQ) has expanded the scope of its marketing and distribution agreement with Orion Corporation (Orion) to commercialize its biosimilars pipeline to include the Baltic states in Europe.

Under the deal, Orion will be responsible for the commercialization of CuraTeQ’s biosimilar products, currently in various stages of development/filing for the partnered territories. CuraTeQ will leverage Aurobindo’s established commercial presence in the nine European markets, including the United Kingdom, France, Germany, Spain, Italy, Portugal to commercialise the biosimilar products in these markets (non-partnered).

“Orion’s understanding of the biosimilars adoption along with extensive commercial infrastructure in the NORDICS and other territories in the EEA make it an ideal partner to expand the accessibility of our biosimilar products in selected markets of Europe, complementing our group’s wide footprint in other European markets,” said Dr Satakarni Makkapati, CEO of CuraTeQ.

Virve Laitinen, SVP Specialty Products of Orion Corporation said, “We are pleased to further expand our long-term collaboration with Aurobindo and CuraTeQ. Overall, this agreement will strengthen Orion’s position as one of the leading generics providers in the Nordics and Baltics as we can make these cost-effective treatments available for health care professionals and patients.”

Earlier in 2020, CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia.

Nithyananda Reddy, Vice Chairman & Managing Director, Aurobindo Pharma Ltd said, ”We remain committed to expanding the reach of our affordable, high-quality products to patients globally and the strengthening of partnership with Orion provides our biosimilar products a pan-Europe access. We are encouraged with our progress on biosimilars development and look forward to execution of the same in the coming years.”

CuraTeQ filed its first oncology biosimilar product with the European Medicines Agency (EMA) in September 2021 and filed its second biosimilar product, also in the oncology segment on January 10, 2022.

At around 1.52 pm, Aurobindo Pharma was trading at Rs723.80 per piece down by 1.92% on Sensex. The stock has touched an intraday high and low of Rs742.25 per piece and Rs713.50 per piece.